Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 401 - 450 out of 3,601

Document Document Title
WO/2006/062110
A compound represented by the formula (I): [wherein R1 represents C3-9 branched alkyl; R2 represents, e.g., linear or branched, C2-9 alkyl optionally substituted by halogen, etc.; and X represents oxygen, etc.] (provided that the followi...  
WO/2006/058648
The present invention relates to compounds of Formula (I) wherein Ar, Ar2, R2, R3, R4, m, p and s are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and...  
WO/2006/050212
The present invention relates to compounds and pharmaceutically acceptable salts of formula I: which are useful in the treatment of metabolic disorders related to insulin resistance or hyperglycemia. These compounds include inhibitors of...  
WO/2006/048620
Liquid crystal compounds of Formula (I) for use in liquid crystal devices contains a dioxatetralin unit within the mesogenic liquid crystal core. The dioxatetralin unit may be located at any position within the mesogenic core of the liqu...  
WO/2006/038606
Disclosed are a compound represented by the formula (I) below, a pharmaceutically acceptable salt thereof, a solvate of those, and a pharmaceutical composition containing such a compound. (In the formula, X1 represents N or CR2; X2 repre...  
WO/2006/034641
The present invention discloses a process for producing Simvastatin and intermediate thereof. The present invention uses inexpensive and available reagent, its condition is mild, and it leaves out the protective and deprotective steps wh...  
WO/2006/030892
The invention aims at providing a process for the production of NS-220 which is suitable for mass production on an industrial scale. The invention is constituted of (1) a process for the production of methyl cis-5-(4-chlorobutyl) -2-meth...  
WO/2006/028972
Mercaptoamide compounds, represented by Formulas (IA), (IB), (IIA), and (IIB): or a pharmaceutically acceptable salt thereof, inhibit histone deacetylase enzyme and are useful for the treatment and/or prevention of various infections, ca...  
WO/2006/024627
The N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein n is 1, 2, 3, or 4; Z represents O, S, NR6, SO or SO2; R1 represent hydrogen, cyano, hydroxy, or C1-4alkyl optiona...  
WO/2006/024627
The N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein n is 1, 2, 3, or 4; Z represents O, S, NR6, SO or SO2; R1 represent hydrogen, cyano, hydroxy, or C1-4alkyl optiona...  
WO/2006/021806
Compounds of formula (I) are useful in treatment of sleep disorders and other conditions mediated by 5-HT2A receptor activity.  
WO/2006/021805
Compounds of formula (I) are potent and selective antagonists of the human 5-HT2A receptor, and hence useful in treatment of a variety of adverse conditions of the CNS.  
WO/2006/022825
Various non-limiting embodiments disclosed herein related to photochromic materials comprising the reaction product of (a) at least one ring-opening cyclic monomer, and (b) a photochromic initiator. Other non-limiting embodiments related...  
WO/2006/018524
The invention relates to a novel method for the synthesis of 2,5-dioxane-1,4-diones having formula (I), comprising the oxidation of the ketone function of a cyclic compound having formula (II), wherein R1, R2, R3 and R4 independently rep...  
WO/2006/018855
Disclosed are novel compounds of general formula (I) where the symbols are as defined in the specification, their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them...  
WO/2006/016708
Conventional many fungicidal compositions have had practical problems such that either a preventive effect or a curing effect is inadequate, the residual effect tends to be inadequate, or the controlling effect against plant diseases ten...  
WO/2006/012227
The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor MR, and pharmaceutical compositions thereof. The compounds of the invention can be useful in the tr...  
WO/2006/007634
The present invention relates to synthetic processes for the preparation of compounds bearing a dioxanyl moiety, in particular to compounds bearing a dioxanyl side chain attached to a mono- or polycyclic core moiety, more particularly a ...  
WO/2006/009134
A novel fungicide that exhibits a wide disease control spectrum against pathogenic fungi acting on various crops and helps resolve worsening resistant strain problems. There are provided diamine derivatives of the formula (1), a process ...  
WO/2006/007435
The present invention is directed to novel sulfamide and sulfamate derivatives, pharmaceutical composlons containing them and their use in the treatment of epilepsy and related disorders.  
WO/2006/007436
The present invention is directed to novel sulfamide and sulfamate derivatives, pharmaceutical compositions containing them and their use in the treatment of epilepsy and related disorders.  
WO/2006/003227
The invention relates to the synthesis of polyoxygenated nitrogen systems, comprising reactions between enamines of 1,3-dioxan-5-ones and nitroolefins. More specifically, the invention relates to the reaction between enamines having form...  
WO/2006/001318
Disclosed are a compound represented by the formula (I) below, prodrugs thereof, pharmaceutically acceptable salts of those and solvates of those. (I) (In the formula, R1 represents an ethyl which may be substituted by a halogen or an am...  
WO/2006/002361
The present invention relates to inhibitors of 11-ß hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the ...  
WO/2005/123710
The invention relates to the derivatives of the benzoylcyclohexandiones of formula (I), wherein R1 and R2 represent different groups and Het represents a saturated heterocyclic group containing oxygen and carbon atoms, and to their use a...  
WO/2005/123712
The invention relates to a method for the synthesis of compounds of general formula (1), (2), (3), (4). Said method consists of converting formulae (5) and (6) in the presence of formula (7), wherein R = substituted or unsubstituted alky...  
WO/2005/123089
Disclosed herein are carbonyl compounds of Formula (I) as described herein. Methods and compositions are disclosed for treating disease states including, but not limited to cancers, autoimmune diseases, tissue damage, central nervous sys...  
WO/2005/123668
The present invention discloses novel compounds of Formula I, or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another ...  
WO/2005/121157
The present invention provides a compound represented by the formula (I): wherein ring A is void or a benzene ring optionally having substituent(s), R1 and R2 are each independently a phenyl group optionally having substituent(s), a cycl...  
WO/2005/118566
A method for producing a 1,3-dioxolan-4,6-dione compound from a ketone compound and a malonic acid, the method comprising: precipitating a 1,3-dioxolan-4,6-dione compound as a crystal from a mixed solvent comprising a first organic solve...  
WO/2005/118530
Disclosed are novel triketone compounds, a method for producing those, and an excellent herbicide containing those. Specifically disclosed are triketone compound represented by the formula (I) below or salts thereof. (I) [In the formula,...  
WO/2005/116119
A compound represented by the formula (I) defined herein, and a process producing the compound represented by the formula (I) which comprises reacting the compound represented by the formula (III) defined herein with the compound represe...  
WO/2005/115972
Compounds of formula I or pharmaceutically acceptable salts thereof: (I) wherein R1, R2, R3, R4, m and n are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are ...  
WO/2005/113527
The present invention relates to novel tetrahydronaphthylpiperazines derivatives, that are compounds of the formula (I) wherein R1, R2 and R6 are as defined herein, X is CH2 or O, A is a group of the formula (G1, G2, G2a, G3, G4, G5 or G...  
WO/2005/111134
An acetal-based composition useful as a nucleating, gelling, thickening or clarifying agent is disclosed. The composition may be synthesized or provided in many different forms, including multicarbon diacetals formed from carbohydrates. ...  
WO/2005/111134
An acetal-based composition useful as a nucleating, gelling, thickening or clarifying agent is disclosed. The composition may be synthesized or provided in many different forms, including multicarbon diacetals formed from carbohydrates. ...  
WO/2005/108479
An acetal-based composition useful as a nucleating, gelling, thickening or clarifying agent is disclosed. The composition may be synthesized or provided in many different forms, including multicarbon diacetals formed from carbohydrates. ...  
WO/2005/108338
The present invention is directed to novel compounds according to formulae (I) wherein R1, R2, R3 and R4 are as defined herein. The invention also discloses methods of preparation, pharmaceutical compositions, and methods of disease trea...  
WO/2005/105744
This invention is directed to a compound of the formula (I) as defined herein, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing a compound of formula I, a method of treatment of a disorder or conditi...  
WO/2005/105776
Compounds of the formula (I) or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein m, n, p, Ar, X, R1, R2, R3, R4, R5 and R6 are as defined herein as well as compositions comprising these compounds and uses of the s...  
WO/2005/105775
For chemical recycling of polylactic acid or derivatives thereof or resin compositions containing them, there is provided a method of efficiently recovering or producing a lactide of high optical purity through depolymerization of polyla...  
WO/2005/100308
The present invention is related to chemical compositions, processes for the preparation thereof and uses of the composition. Particularly, the present invention relates to compositions that include substituted biaryl-methanesulfinyl ace...  
WO/2005/100301
The present invention relates to certain 2-aryloxyethyl glycine derivatives that exhibit activity as inhibitors of the glycine type-1 transporter, to pharmaceutical compositions containing them and to their use in the treatment of neurol...  
WO/2005/100345
The present invention is related to chemical compositions, processes for the preparation thereof and uses of the composition. Particularly, the present invention relates to compositions of compounds of Formula (A): wherein Ar, Y, R1 and ...  
WO/2005/097773
The present invention is related to carboxylic acids of Formula (I) and use thereof for the treatment and/or prevention of obesity and/or metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type I and...  
WO/2005/094805
A medicine having prostaglandin D2 (PGD2) production inhibitory activity and having as an active ingredient a substance selected from compounds represented by the general formula (I): A-Y-B &lcub wherein A and B each independently repres...  
WO/2005/095343
The invention relates to compounds of formula (I), Z-C(R1R2)-C(R3NH2)-C(R4R5)-X-N(R6R7), wherein Z, R1-7 and X have the meaning as cited in the description and the claims. Said compounds are useful as DPP-lV inhibitors. The invention als...  
WO/2005/095378
The present invention is directed to carboxylic acid and ester moieties that are attached to a carbon chain that is between 2 and 24 carbons in length wherein, the chain contains at least one dioxanone ring system, said dioxanone being f...  
WO/2005/087236
Muscarinic Acetylcholine receptor antagonists and methods of using them are provided.  
WO/2005/083102
It is intended to provide a novel process for producing an optically active 1,4-benzodioxin-2-carboxylic acid derivative, which is usable as an intermediate in synthesizing an optically active drug, via biological conversion. Namely, a 6...  

Matches 401 - 450 out of 3,601